Novartis' kidney product portfolio makes its debut at the China International Import Expo, and the company stated that it will actively promote the product's launch
海角七号
发表于 昨天 17:22
116
0
0
The 7th China International Import Expo (CIIE) is currently being held. The reporter saw at the scene that Novartis' innovative drug combination for the treatment of IgA nephropathy (IgAN), including atorvastatin and fexostat (Ipropan hydrochloride capsules), made its first joint appearance. The reporter further learned from Novartis that Novartis plans to launch a "combination punch" in the field of kidney disease. Atractylodes, Ipropan Hydrochloride Capsules, and another investigational product Zigakibart will be important components of Novartis' product pipeline in the field of kidney disease, covering six major indications and rewriting the diagnosis and treatment status of IgA nephropathy and other kidney diseases in China, "the company said.
Further information shows that atorvastatin is the first non immune, highly selective IgAN precision therapy drug submitted for market in China. Ipropan Hydrochloride Capsules received accelerated approval from the US Food and Drug Administration in August this year to reduce proteinuria in adult IgA nephropathy patients at risk of rapid progression. It is currently the world's first complement bypass pathway inhibitor approved for this indication; At present, the indication of using Ipropan Hydrochloride Capsules for the treatment of paroxysmal nocturnal hemoglobin (PNH) has been approved in China, and the application for expanding indications in the field of kidney disease has also been accepted by the China National Medical Products Administration.
Li Yao, President and Managing Director of Novartis China, stated that the new kidney product portfolio showcased at the CIIE is expected to provide more accurate and safe solutions for the treatment of kidney diseases in China. "We will actively promote the simultaneous launch of these innovative drugs domestically and globally, and use 'Chinese speed' to benefit more kidney disease patients
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Vipshop's "Global Good Port" Appears at the Consumer Expo and Releases V-Global Investment Plan for the First Time
- Interview with Consumer Expo | He Tianxing, Vice President of Yihang Intelligence: Ask Sky for the Core Value of GDP Low Altitude Economy in the Future or Consumption
- Vipshop launches V-Global Global global investment plan at the Consumer Expo
- Sony will participate in the 2024 China International Import Expo
- Establishing a green channel for high-quality brands, Vipshop is seeking gold at the Shanghai International Import Expo
- 2024 CIIE | Abbott's dual chamber wireless cardiac pacemaker makes global debut
- Ericsson China President Fang Ying: CIIE provides a shared innovation platform for global enterprises
- Novo Nordisk's biggest revenue contributor in the third quarter, Simeglutide, made its debut at the CIIE
- Dingdong Maicai's "Buyer Team" plans to "Buy Global" at the China International Import Expo, with purchase orders reaching over 100 million yuan
- 2024 Enter the Expo | Improve local innovation ability, Nike digs gold in China's running market
-
随着“银十”结束,各家造车新势力都交出了一份亮眼的成绩单。 理想领跑10月新势力交付榜,鸿蒙智行重回4万辆,零跑、深蓝、极氪、小鹏等单月交付量均创新高,岚图、阿维塔、智己等实现破万,但哪吒却消失在 ...
- fanadam
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
为期超七周的大罢工终于落下帷幕。 当地时间11月4日,波音美国西海岸工厂工人们就改进后的合同提案投票。 随后,代表着波音超过33000名西雅图地区机械师的IAM工会经表决,以59%的同意票决定接纳波音提 ...
- cristianna
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
“新四化”的时代浪潮下,新能源汽车行业百家争鸣。伴随着自主品牌不断崛起,合资品牌当下的生存状况备受外界关注,如何打好电动化时代的突围战,成为合资品牌的新课题。 作为国内合资车企的代表之一,上汽 ...
- mbgg2797
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
证券时报网讯,热门中概股美股盘前普涨,小鹏汽车、哔哩哔哩涨近5%,蔚来涨超4%,阿里巴巴、拼多多涨超2%。
- p609520
- 3 天前
- 支持
- 反对
- 回复
- 收藏